We found that the PCs (whether aberrant or normal) analyzed in patients with inactive and active MM expressed similar levels of CD24 however, MM cells of patients in remission after chemotherapy treatment, showed significantly higher CD24 expression on the PCs since these patients have less or no aberrant PCs a more normal CD45+CD19+CD56- immunophenotype is observed (Figure 6B, p < 0.05). The gene discussed is PTPRC; the disease is Miyoshi myopathy.